H.C. Wainwright raised the firm’s price target on Lexeo Therapeutics (LXEO) to $15 from $9 and keeps a Buy rating on the shares after the company announced that the FDA has indicated openness to a BLA submission for accelerated approval that includes clinical data from the ongoing Phase I/II studies of LX2006 pooled with new clinical data to be generated in the planned pivotal study. Following the formal FDA alignment, the firm is raising its view of the odds of approval to 50% from 40% and advancing the expected launch to 2028 from 2030, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target
- Lexeo Therapeutics price target raised to $20 from $9 at Leerink
- Morning Movers: IntercontinentalExchange up after $2B investment in Polymarket
- Lexeo Therapeutics up 31% at $8.50 after update on LX2006 accelerated approval
- Lexeo Therapeutics Advances FDA Discussions for LX2006